Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026

Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented...

Over a Thousand Developers Pursue the Dream of Open Computing! FlagOS Open Computing Global Challenge Season 1 Award Ceremony Featured at the 8th BAAI Conference

Over a Thousand Developers Pursue the Dream of Open Computing! FlagOS Open Computing Global Challenge Season 1 Award Ceremony Featured at the 8th BAAI Conference

BEIJING, June 16, 2026 /PRNewswire/ -- On June 13, the award ceremony for the FlagOS Open Computing Global Challenge (Season 1), jointly organized by the Beijing Academy of Artificial Intelligence (BAAI) and the FlagOS Community, was held during the...

ACON OPTICS (TWSE: 6820) Strengthens AI High-Speed Interconnect Portfolio with CPO and 1.6T Connectivity Technologies at COMPUTEX 2026

ACON OPTICS (TWSE: 6820) Strengthens AI High-Speed Interconnect Portfolio with CPO and 1.6T Connectivity Technologies at COMPUTEX 2026

TAIPEI, June 16, 2026 /PRNewswire/ -- ACON OPTICS (TWSE: 6820), a leading provider of advanced optical connectivity solutions, showcased its latest innovations in AI optical interconnect technologies at COMPUTEX 2026 under the theme "Shaping...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc...

As AI Infrastructure Takes Center Stage, Neurovia AI Highlights NeuroStream™ and New Leadership at UAE Industry Summit

As AI Infrastructure Takes Center Stage, Neurovia AI Highlights NeuroStream™ and New Leadership at UAE Industry Summit

ABU DHABI, UAE, June 11, 2026 /PRNewswire/ -- Robo.ai Inc. (NASDAQ: AIIO) announced that its wholly-owned subsidiary, Neurovia AI, officially participated in the 2026 UAE Data Center Infrastructure & Cloud Summit as an OFFICIAL AI INFRASTRUCTURE...

HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations

HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations

TAIPEI, June 10, 2026 /PRNewswire/ -- HKC, ANTGAMER, and KOORUI have successfully concluded their presence at COMPUTEX 2026. Under the theme "Win Beyond the Frame," the three brands unveiled multiple world-first display products and advanced...

INVT Unveils "Smart + Net-Zero" Strategy and New Product Portfolio at 2026 Global Launch Event

INVT Unveils "Smart + Net-Zero" Strategy and New Product Portfolio at 2026 Global Launch Event

SUZHOU, China, June 8, 2026 /PRNewswire/ -- Leading industrial automation and energy solution supplier INVT successfully held its Global Strategy and New Product Launch 2026 under the theme of i lluminated Voyage, Awakened Wisdom. During the event,...

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...

Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting

Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting

HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today announced updated...

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, June 1, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • menu
    menu